Literature DB >> 11836665

The epidemiology of mesothelioma.

Mark Britton1.   

Abstract

It has been more than 40 years since occupational crocidolite exposure in South African miners was found to be associated with development of malignant mesothelial tumors 30 to 40 years later. Similar cases were not seen in the amosite and chrysotile miners. Since then, epidemiological and toxicological knowledge have increased enormously, but mortality continues to rise steeply (5% to 10% per year) in most industrialized countries. Even with widespread asbestos abatement efforts, this increase is likely to continue in Western Europe and the United State well into the next century, at least until 2020. Unregulated use of asbestos in less industrialized countries may cause the epidemic to continue throughout the next century in those regions. Asbestos abatement seems to be successful as evidenced by a decline in the proportion of patients with peritoneal tumors, which are the most common malignancies in heavily exposed individuals. Whereas in the 1960s peritoneal tumors comprised up to 30% of the total, in recent years the proportion has fallen to about 10%, This changing ratio could also be due to the steady increase in pleural tumors. The difficulty in formulating the connection as to the etiology of mesothelioma resulted from an unforeseeable difference in the carcinogenicity of various asbestos and mineral fiber types and was compounded by the very long latency of the disease. Unfortunately, the use of a single term, "asbestos," to describe at least five fibrous silicate minerals, each with unique physical, chemical, and biological properties and not infrequently and naturally admixed, severely hampered scientific investigation into the occupational health risks. The field became confused and filled with debate. At the heart of the fiber type controversy lies a fundamentally differing view of the importance of biopersistence of various asbestos fibers in carcinogenesis. This review will deal with the epidemiology of mesothelioma with particular attention to the studies that elucidate the impact of various asbestos fiber types on the etiology of the disease. Copyright 2002 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836665     DOI: 10.1053/sonc.2002.30237

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  37 in total

Review 1.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

2.  Chrysotile and rock wool fibers induce chromosome aberrations and DNA damage in V79 lung fibroblast cells.

Authors:  Yan Cui; Ji Ma; Wei Ye; Zhixia Han; Faqin Dong; Jianjun Deng; Qingbi Zhang
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-07       Impact factor: 4.223

3.  A Rare Complication of Diffuse Malignant Peritoneal Mesothelioma: Spontaneous Ileal Perforation.

Authors:  Orhan Kalaycı; Güven Barış Cansu; Bengür Taşkıran; Özlem Eren
Journal:  Indian J Surg Oncol       Date:  2019-04-06

4.  Validation of genomics-based prognostic tests in malignant pleural mesothelioma.

Authors:  Gavin J Gordon; Graham N Rockwell; Paul A Godfrey; Roderick V Jensen; Jonathan N Glickman; Beow Y Yeap; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

5.  Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Authors:  Gavin J Gordon; Graham N Rockwell; Roderick V Jensen; James G Rheinwald; Jonathan N Glickman; Joshua P Aronson; Brian J Pottorf; Matthew D Nitz; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

6.  Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.

Authors:  Esther Z Chen; Blake A Jacobson; Manish R Patel; Aniekan M Okon; Shui Li; Kerry Xiong; Abhishek J Vaidya; Peter B Bitterman; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2014-04-09       Impact factor: 3.850

7.  miR-1 induces growth arrest and apoptosis in malignant mesothelioma.

Authors:  Yue Xu; Ming Zheng; Robert E Merritt; Joseph B Shrager; Heather A Wakelee; Robert A Kratzke; Chuong D Hoang
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

8.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Martina Skrede; Hiep Phuc Dong; Søren Nielsen; Michael T McMaster; Jahn M Nesland; Ie-Ming Shih; Ben Davidson
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

9.  Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities.

Authors:  Shulamit Sebban; Ben Davidson; Reuven Reich
Journal:  Virchows Arch       Date:  2008-11-18       Impact factor: 4.064

10.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.